ReviewVeterinary and animal science2026
Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies.
Review in Veterinary and animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Avian influenza viruses (AIVs), particularly highly pathogenic H5 and H7 viruses, pose major threats to poultry production, food security, international trade, and public health. Vaccination is an important component of AIV control; however, antigenic evolution, incomplete reduction of viral shedding, and challenges associated with large-scale poultry vaccination limit its effectiveness. In addition to conventional vaccines, recombinant and nucleic-acid platforms have emerged in response to rapidly evolving AIVs. Methods: Relevant literature on inactivated, live attenuated, recombinant subunit, viral-vector, DNA, mRNA, and virus-like particle vaccines was evaluated. Immune responses, protection, antigenic breadth, viral shedding, delivery, manufacturing, field applicability, and regulatory considerations were analyzed. Results: Inactivated vaccines are well-established, safe, scalable, and cost-effective but provide limited cellular and mucosal immunity and require antigenic matching. Live attenuated vaccines can induce broader immunity and facilitate mass vaccination but present biosafety, reassortment, and genetic-stability concerns. Next-generation platforms provide greater antigenic flexibility and opportunities for broader protection. Viral-vector vaccines can induce both humoral and cellular immunity, while recombinant subunit, DNA, mRNA, and VLP vaccines offer rapid redesign and multivalent formulations. However, challenges remain regarding delivery, stability, manufacturing, durability, and field validation. Conclusions: No single platform currently meets all requirements for sustainable AIV control. Future strategies should emphasize conserved or mosaic antigens, durable and mucosal immunity, rapid vaccine updating, DIVA compatibility, and scalable delivery. Combining conventional and emerging platforms through prime-boost or multi-platform strategies may provide more flexible and effective control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.